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The  lymphokine-activated killer  cell  (LAK) 1 system  has  been  reported  by us  to 
represent  a  cytotoxic phenomenon distinct from either the classic cytotoxic thymus- 
derived lymphocyte (CTL) or natural  killer  (NK)  cell  system on the basis of devel- 
opment kinetics,  stimulus requirement, cytotoxic specificity, precursor location, and 
serologic phenotype of the LAK effector cells  (1). The LAK system is unique in  its 
simplicity of activation, since culture of nonadherent peripheral  blood lymphocytes 
(PBL) for a minimum of 3 d in lectin-free lymphokine preparations rich in interleukin- 
2  (IL-2)  is  the  only  requirement.  As  described  earlier  (1),  the  LAK phenomenon 
involves  an  activation  mechanism  that  may  be  common  to  the  many  reports  of 
nonclassic  culture-induced  lymphocyte-mediated cytotoxicities  such  as  the  mixed 
lymphocyte/leukocyte culture  induced anomalous killers  (2-6), NK-like killers  (7, 8), 
fetal calf serum-induced killers  (9-11), and lectin-induced killer cells  (12). Therefore, 
this  system  is  a  most  likely  candidate  for unifying the  growing body of literature 
concerning these  cytotoxicities,  and  for  approaching  the  study  of their  biological 
significance. 
LAK can  be  generated  from  PBL  of >90%  of the  cancer  patients  tested.  One 
potential significance of the LAK cells is that they can efficiently lyse fresh single-cell 
suspensions of autologous fresh tumor cells, in addition to allogeneic fresh tumors and 
all cultured tumors tested, including those that are NK-resistant  (1,  13), all of which 
LAK lyse optimally in a 4-h chromium-release assay. Since as yet no reproducible or 
consistent method is available for generation of human antitumor CTL, the potential 
for  LAK  as  an  important  antitumor  defense  mechanism  has  encouraged  further 
definition of the system. We have shown previously that the precursor of the LAK cell 
is nonadherent to plastic or nylon wool, and that its  activation can be prevented by 
2,000  rad of gamma irradiation.  Therefore we studied  in  parallel  the phenotype of 
the  effectors and  precursors  of LAK cells,  NK  cells,  and  CTL  and  confirmed  the 
distinct  functional  nature  of each  system  by simultaneous  activation  cultures  and 
1 Abbreviations used in  thi~ paper." C', complement; CM, complete medium; C-IL-2, crude IL-2; CTL, 
cytotoxic thymus-derived lymphocyte; ttBSS, flanks' balanced salt solution; IL-2, interleukin 2; IVS, in 
vitro sensitizatkm; LAK, lymphokine-activated killer cell; LGL, large granular lymphocyte; I.SM, lym- 
phocyte separation medium; NK, natural killer; PBL, peripheral blood lymphocyte; PBS, phosphate- 
buffered saline; PIIA,  phytohemagglutinin; SRBC, sheep erythrocyte. 
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subsequent  cytotoxicity  assays.  The  results  presented  in  this  manuscript  further 
confirm the uniqueness of the LAK system, since the precursor was  found by both 
serologic and morphologic selection techniques to be different from peripheral blood 
T  lymphocytes, NK cells, and memory CTL. 
Materials and Methods 
PBL.  PBL were obtained from normal volunteers and cancer patients by fractionation of 
peripheral blood cells  on LSM gradients (Litton Bionetics, Kensington, MD)  as  previously 
described (6). The cells were washed  twice with Hanks' balanced salt solution (HBSS)  and 
resuspended in complete medium (CM) consisting of RPMI 1640 (Gibco Laboratories, Grand 
Island Biological  Co.,  Grand Island, NY)  containing 10% heat-inactivated human AB serum 
(KC Biologicals, Kansas City, MO), 100 U/ml penicillin,  and 100/~g/ml streptomycin (National 
Institutes of Health [NIH] Median Unit). PBL were used fresh  or cryopreserved and subse- 
quently thawed when needed. Blood from cancer patients was drawn before surgery or at least 
2 wk after surgery. Adherent cells were removed after suspending the PBL in CM at 3 ×  107/ 
ml, by placing into plastic tissue culture plates (Falcon 3023; Falcon Labware, Div. of Becton, 
Dickinson & Co.,  Oxnard, CA)  for  1 h  at  37°C. The nonadherent cells were  gently washed 
from the plates and incubated in CM on scrubbed nylon wool columns for 60 min at 37°C. 
Fresh Solid Tumor Cell Targets  from Surgical Specimens.  The preparation of single-cell suspensions 
from fresh tumor specimens was performed as described in detail previously (1). Briefly, fresh 
surgical specimens were collected and kept in HBSS at 4°C for processing.  Necrotic tumor and 
connective tissues  were  dissected,  and  the  remaining tumor  tissue  was  minced  in  HBSS 
containing  5 U/ml hyaluronidase, 2 mg/ml collagenase, and 0.2-0.3 mg/ml deoxyribonuclease. 
The tumor fragments were further dissociated by trypsinization using mechanical stirring in 
flasks with  10-20 ml of 0.25%  trypsin in Dulbecco's phosphate-buffered saline with EDTA 
without calcium or magnesium (NIH Media Unit) for  10 rain. The resuhing cell suspension 
was decanted into a  tube containing heat-inactivated human AB serum, pelleted, and resus- 
pended in 20-50 cm  3 of CM. An aliquot was sent for cytologic analysis, and the rest was used 
either immediately or cryopreserved in 90% human AB serum plus 10% dimethyl sulfoxide for 
future use. All samples were analyzed by the NIH Cytopathology Department using Papani- 
colaou staining to determine the percentage of tumor cells. All tumor preparations used in this 
study contained >80% malignant ceils, and are identified further in the Results section as to 
the histologic type. 
Cultured Tumor Targets.  K562, the NK-sensitive myeloid leukemia line was cultured in CM, 
and passaged weekly. 
Serologic Depletion Studies.  PBL were washed twice in HBSS and resuspended at  1 ×  10V/ml 
at 4°C. The previously determined optimal dilution of monoclonal antibody was added directly 
to the cells (1:20 dilution for OKT-3, OKT-8, OKT-4, OKM-1, and Leu-7 and 1:50 for Leu-1 
and OKT-11); the OKT reagents were purchased from Ortho Pharmaceutical Corp., Raritan, 
N  J, and the Leu reagents from Becton, Dickinson & Co., Sunnyvale, CA. Antibody incubation 
was performed for 1 h at 4°C with occasional mixing. The cells were pelleted, and complement 
(C')  was added in HBSS. Newborn rabbit serum was used as a source of C' and was found to 
be optimal at a  1:6 dilution. C' lysis was performed at 37°C for  1 h, after which the cells were 
washed  once  in  HBSS,  resuspended  in  CM,  and  counted  for  viability using trypan  blue 
exclusion. 
Percoll Gradient Separation of T Cells and Large Granular Lymphocytes (LGL).  The nonadherent 
PBL cells were resuspended at  5  ×  107/ml  in CM supplemented with  10% AB serum, and 
separated by centrifugation on a discontinuous  gradient of Percoll (Pharmacia Fine Chemicals, 
Uppsala, Sweden) modified from the method described by Timonen et al.  (14). Briefly,  the 
100% Percoll and CM were  adjusted to 285 mosmol/kg H20 with  10 ×  phosphate-buffered 
saline (PBS, pH 7.2) (Gibco Laboratories). Final concentrations of Percoll were prepared, at 40, 
42,  45,  47,  50,  52,  and 55%, or as  described  in the experiment. After carefully layering the 
fractions into 15-ml conical tubes (Falcon 2095), we layered I ml of nonadherent cells onto the 
top of the gradient, and centrifuged them at 550 g for 20 rain at room temperature (or longer 
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the top with a  Pasteur  pipette,  and  washed  in  CM. Cells from the NK-rich  Percoll fraction 
(-45%  Percoll)  (containing  LGL)  were  further  depleted  of low-density  T  lymphocytes  via 
rosette formation with sheep erythrocytes (SRBC) for 2 h at 29°C (15). The non-rosette forming 
cells were >70% LGL. Preparations  of unseparated  nonadherent  cells, LGL from the NK-rich 
Percoll fraction and 29°C SRBC rosetting, and T  cells from the high-density (50  60%)  Percoll 
fractions were then coded before further studies were performed. 
Isolation by Panning.  LAK precursors were separated  from T  cells found in fresh PBL by the 
panning  procedure  described  in detail by Engleman  et  al.  (16),  except  that  human  agamma 
serum  was  substituted  for  fetal  calf  serum.  Briefly,  nonadherent  PBL  were  washed  and 
resuspended in PBS at  107/rnl. These cells were then incubated with various dilutions of either 
Leu-1 or OKT-3 for 20 nfin at room temperature.  (We found the optimal quantities to be 0.01 
ml of Leu-1  and 0.075  ml of OKT-3). 
After two washes with PBS, the cells were resuspended  in 4 ml of PBS containing 5% serum, 
added to plates previously coated with affinity-purified goat anti-mouse IgG (Kirkegaard  and 
Perry, Gaithersburg,  MD), and incubated at 4°C for 2 h. Nonadherent  cells were removed by 
gently swirling off the PBS, followed by one rinse with PBS. Adherent cells were removed by 
vigorous pipetting, and in some experiments by use of trypsin. All cells were then washed and 
resuspended  in CM.  The  effectiveness of this  panning  procedure  was  confirmed  by  positive 
panning of allospecific CTL. 
IL-2 Preparation and Partial Purification.  Crude T  cell growth factor was either purchased from 
Associated  Biomedic Systems  (Buffalo,  NY)  or prepared  by  us  using  a  previously  discussed 
modification (17)  of our original method  (18).  In brief, PBL at 5 X  106/ml were incubated  in 
RPMI  1640  containing 2% human  AB serum and 0.2% phytohemagglutinin  (PHA-P)  (Difco 
Laboratories,  Detroit,  MI). The 2-d culture supernatant  was collected by eentrifugation  and 
used as crude IL-2  (C-IL-2).  Partial  purification and  removal of the PHA from these C-IL-2 
preparations was performed as we described previously (19).  In brief, the C-IL-2 was brought 
to 50% saturation with ammonium sulfate and the precipitate discarded. The supernatant  was 
then raised to 75% saturation, the precipitate collected, resuspended in water to achieve an ~ 1/ 
10  vol of C-IL-2 starting  sample,  dialyzed  first  vs. water,  then  vs.  PBS,  and  passed  over an 
affinity  column  (14  ×  0.9  cm)  of Sepharose  4B  (Pharmacia)  coupled  to  rabbit  anti-PHA 
antibody.  Tests  for IL-2 activity were performed  using  IL-2-dependent  human  PBL  after at 
•  3  •  ,  least  14 d m  culture. Both short-term  [ H]thymldlne uptake assays and  7-d growth assays were 
used to determine optimal IL-2 titer. 
Primary and Secondary In  Vitro Sensitization for CTL  Generation.  Primary  in vitro sensitization 
(IVS) was performed by co-culture of responder PBL with stimulator PBL incubated vertically 
in CM in Falcon 3013  flasks  (20).  Responder  PBL were used at  a  final concentration  of I  X 
106/ml  in CM.  Irradiation  of PBL stimulator cells was  performed using a  cesium-137 source 
(Isomedex Inc., Parsippany, N  J) at 2,000 rad. Stimulator cells were washed once after irradiation 
and added  at  1 ×  106/ml. Primary CTL were tested on day 7 ofcuhure. 
Memory CTL were prepared  by washing primary CTL with fresh CM, and reculturing for 
7 d more at  1 ×  106/inl. Serologic depletion studies were performed on day  14, after which time 
the memory cells were harvested  (resulting in _--<25% of original cells) and again recultured  at 
1  ×  106/ml  in  CM  containing  the  optimal  dilution  of IL-2  previously  titrated  to  activate 
memory cells into secondary CTL. The secondary CTL activity was then assayed on day  18. 
Activation of LAK by Partially Purified IL-2.  LAK were generated by culture of responder PBL 
at  1 ×  106/ml  in CM  at  the dilution of IL-2 determined  to be optimal  for growth  of IL-2- 
dependent  cells  (usually  1:10  for our  10-fold-concentrated  partially  purified  IL-2),  and  also 
titrated to be optimal for LAK activation. Cultures were for 6-7 d  unless stated otherwise, 
Measurement of Cytotoxicity.  A 4-h '~ICr-release assay was used to measure cytotoxicity of fresh 
tumor or PBL target cells, Target cells were thawed the morning of the assay, and labeled with 
400/.tCi of NaSlCrO4 (Amersham Corp., Arlington Heights, IL) for 120 min in 0.5 cm  :~ of CM. 
The cells were then washed  four times with CM  and  added  at  5  ×  10  ,3 cells/well to various 
numbers  of the effector lymphocytes  in round-bottomed  miccotiter plates  (Linbro  Chemical 
Co., Hamden, CT). The plates were centrifuged at 500 rpm for 3 min and incubated for 4 h  at 
37°C,  5%  CO2.  The  culture  supernatants  were  harvested  with  the  Skatron-Titertek  System 
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was produced by incubation of the targets with 0.1 N HCI. Spontaneous release was determined 
by incubation of targets with CM alone. Fresh tumor targets were found to express between 10 
and  30%  spontaneous  release  during  the  4-h  assay.  The  percentage  of specific  lysis was 
calculated by the formula: ([experimental epm -  spontaneous epm]/[maximal cpm -  sponta- 
neous cpm]) ×  100%. All determinations were made in triplicate and data are reported as the 
mean _+ SEM. 
Lytic units were calculated by extrapolating the number of effector cells required to cause 
33.3% lysis of 5 ×  103 tumor or PBL target cells. 
Preparation of Lymphoid Ttksues.  Human  thymus  (generously provided by Dr. Jack  Roth, 
Surgery Branch, National Cancer Institute [NCIt, NIH) spleen and lymph node, was processed 
immediately after surgical resection from cancer patients. The tissues were minced at  room 
temperature in  HBSS,  and  the dissociated cells were separated by filtration through  nylon 
mesh. The erythrocytes were then removed by fractionation on LSM gradients as described for 
PBL. The mononuclear cell fraction was collected, washed, and cryopreserved until thawed for 
use  in  these experiments.  Bone  marrow  cells were  the  generous  gift of Dr.  Thomas  Sharp 
(Surgery Branch, NCI, NIH). The marrow cells were rinsed from the vertebrae body ofa 23-yr- 
old  cadaveric  donor  without  cancer.  They  were  further  processed  as  for  the  PBL,  and 
cryopreserved until used. 
Results 
LAK Effector Cells Express  the Serologic Phenotype of Allospecific  CTL.  In our previous 
report  (1)  we showed  that  the autologous and  allogeneic antitumor killer cells were 
generated by culture of PBL in partially purified preparations of IL-2; the resulting 
LAK effector cells are sensitive to C' lysis by monoclonal antibodies known to identify 
allospecific  CTL.  These  LAK  effectors  were  extremely  sensitive  to  Leu-1  (95% 
reduction)  and  partially  sensitive  to  the  OKT-3  and  4F2  (63%  and  62%)  T  cell 
reagents  and  appeared  insensitive  to  the  monocyte-NK  cell  marker  OKM-I  (1). 
Therefore,  to  determine  the  subclass  of T  cells  mediating  antitumor  lysis and  to 
directly compare their phenotype with that of CTL, we prepared LAK and CTL in 
parallel from the same responder PBL, and after activation tested their sensitivity to 
a  variety of monoclonal  anti-T  cell  subclass  antibodies  (Table  I).  Both  LAK  and 
CTL effector ceils were found to be insensitive to the inducer-helper T  cell antibody 
OKT-4 (21)  (7% loss of activity), minimally sensitive to the monocyte/NK cell marker 
OKM-1  (22)  (25% loss of activity), partially sensitive to the pan T  cell reagent OKT- 
3 (23)  (80% loss of activity), and extremely sensitive to the cytotoxic/suppressor T  cell 
antibody OKT-8  (23)  (90% and  71%  loss of activity). The OKT-3 reagent has never 
been able to eliminate all LAK activity, even when the pan T  Leu-1 reagent (24)  did 
(1);  therefore it was of interest to observe that  OKT-3  plus C' did not eliminate all 
CTL  activity  either.  Thus  LAK  effector  activity  to  autologous  tumor  and  CTL 
activity to the specific sensitizing allogeneic cell were eliminated to relatively similar 
degrees by the same monoclonal antibodies. 
LAK  effectors  appeared  morphologically  to  be  rather  large  cells  when  we  at- 
tempted to separate the LAK from  CTL  by sedimentation on  Percoll gradients.  In 
data not shown,  we found  that  the LAK and  the CTL both sedimented in the 45% 
band. Since this area is identical to that for NK cell sedimentation, it is interesting to 
speculate that all cytolytic lymphocytes are larger cells of low density. 
LAK Precursor Cells Are Distinct from  Those  Required for  CTL  Generation.  Although 
LAK effector cells express the serologic phenotype of CTL,  the LAK system differed 
from the primary CTL system in two major aspects: a more rapid kinetics of induction 
was seen for LAK (day 3 vs. days 6-7), and no known antigenic stimulus was required 888  II,-2  ACTIVATED  KILLER  CEI,LS  DISTINCT  FROM  NK  AND  T  CELLS 
TABLE  I 
Monoclonal Antibody Depletion of Autologous LAK  vs.  CTL  Effector Function 
Experi-  Treatment* 
ment 
Post-lVS  Post-II,-2 
Percent  CTL  Percent  I,AK§ 
cells lysed}  activity  cells lysed  activity 
l,{ ql/ l O  ~ celL~  I,U/ I O  6 celL~ 
1  C'  0  2O  0  50 
OKM-1  +  C'  0  I5  i3  40 
OKT-3 +  C'  27  4  13  25 
OKT-8 +  C'  39  2  37  7 
2  C'  0  14  0  4.5 
OKT-4 +  C'  63  13  54  4.5 
OKT-8 +  C'  29  4  36  0.5 
* PBL from cancer patients were incubated for 7 d in a primary allogeneic IVS in one set of 
cultures, and with IL-2 in another. After treatment CTL lysis was tested toward fresh PBL 
targets autologous to the stimulator cell used in the IVS cultures, and LAK lysis tested to 
the autologous tumor target. 
:~ The percent cells lysed was determined by trypan blue exclusion counts of viable cells. 
§ The autologous tumor targets were  uncultured single-cell preparations  of melanoma in 
experiment 1, and sarcoma in experiment 2. 
1[ Lytic units. 
TABLE  II 
Sensitivity of Cells Required to Generate CTL vs.  LAK  to Monoclonal 
Antibodies plus C' 
Lytic units, 106 cells 
Percent cells 
Treatment*  lysed:]:  CTL Allo-PBL  LAK tumor tar- 
targets post-lVS  gets§ post-IL-2 
culture 
None  0  I0.5  I 1.0 
C' only  9  8.7  ND[I 
OKT-3 +  C'  56  <l  62.0 
OKM-I +  C'  17  20.0  9.0 
Leu- 1 +  C'  63  <1  66.0 
* Nonadherent  PBL were  divided  into  five groups and treated  as described. 
The nonlysed PBL  from each treatment group were then divided equally, 
adjusted to the concentration of the untreated cells, and used as responders 
in an IVS or incubation with IL-2. 
:~ The percent cells lysed was determined by trypan blue exclusion counts for 
viable cells. 
§ The tumor targets used were from a  single-cell suspension of fresh undiffer- 
entiated sarcoma. 
II Not done. 
for  LAK  (1).  Therefore  to  further  define  the  LAK  phenomenon  in relationship  to  the 
CTL  system, we tested whether  LAK  precursor  cells expressed  any serologic similarities 
with  CTL  precursor  cells.  Table  II  shows  the  results  from  one  of two  experiments  in 
which  fresh  PBL  were  treated  with  monoclonal  antibodies  plus  C'  and  then  divided 
for  use  as  responders  in  both  LAK  and  allogeneic  CTL  activation  cultures.  As 
expected,  the  generation  of  allospecific  CTL  was  totally  eliminated  by  killing  the 
precursors  expressing  the  pan  T  antibodies  OKT-3  or  Leu-1  (24);  however,  the 
development  of LAK  activity  from  these same  depleted  populations  was  found  to  be GRIMM,  RAMSEY, MAZUMDER,  WILSON, DJEU,  AND ROSENBERG 
TABLE III 
Monoclonal Anti- T  Cell Antibodies  Ehminate Allospec~'c  Memory  CTL but not LAK 
Precursors* 
889 
Lyric units, l0  s cells 
Experi-  Treatment  Percent  LAK  Memory CTL 
ment  cells lysed:~ 
Targets/  Specific  Self-PBL 
tumor~  alIo-PBL 
None  0  4.0  10.0  < 1 
C' only  24  5.6  16.0  <1 
OKT-3 + C'  94  >20.0  1.4  <1 
OKT-8 + C'  57  4.4  <1  <l 
Leu-1 + C'  95  >20.0  1.0  <1 
C' only  40  16.6  20.0  NDII 
OKT-3 + C'  90  33.3  <1  ND 
OKM-1 + C'  86  10.0  15.0  ND 
Leu- 1 + C'  95  50.0  < 1  ND 
* Memory CTL were prepared as described in Materials and Methods. On day  14, the 
memory cells were harvested and treated as shown, then recultured in IL-2 for 4 d more. 
The 2  ° CTL were then tested for lysis  of the targets shown. 
:~ The percent cells lysed was determined by trypan blue exclusion counts. 
§ The tumor target cells used were a fresh malignant fibrous histiocytoma for experiment 1, 
and a malignant hemangiopericytoma for experiment 2. 
II Not done. 
dramatically augmented (five- to sixfold increase in lytic units). The anti-monocyte/ 
NK cell antibody OKM-1 had little effect on either system. In experiments not shown, 
it was found that culture of cells treated with antibody alone (but not with C') were 
not activated unless IL-2 was added, and that in the case of OKT-3, the presence of 
the  antibody  at  the  concentration  used  for  lysis  suppressed  LAK  development. 
Therefore, our results indicate that lysis of the T  ceils by specific antibody and C' did 
not  interrupt  subsequent  activation  by  IL-2  in  the  case  of  LAK  but  eliminated 
alloantigen reactivity in the case of CTL. 
Panning techniques were also employed to positively select for T  cells and to test 
the serologic phenotype of the  LAK precursors.  OKT-3 antibody was used in nine 
experiments with an average of 55.6 +  5.9% of the cells adhering, and Leu-1 was used 
in four experiments yielding 50.5  +  5.8% of cells adhering. Adherent, nonadherent, 
and unseparated PBL populations were then tested for ability to generate CTL and 
LAK. The nonadherent populations were found to be enriched in LAK precursors (2- 
to  17-fold increase of LAK generation). However, variable results were obtained with 
generation of CTL  from  the  adherent cells.  It  was  found that  the  presence of the 
antibodies significantly inhibited CTL generation, and even after trypsin treatment 
of the OKT-3 or Leu-1-positive panned cells, we were able to generate very little CTL 
activity. A recent report by Reinherz et al. (25) describing antigen nonresponsiveness 
after OKT-3 antibody modulation of the T3 molecule, provides the explanation for 
our lack of function by the adherent cells. Therefore, by the positive selection of T 
cells, we have found LAK precursors to be present in the OKT-3 and Leu-1 negative 
population; however,  the  activity of the  purified T  cell  populations could  not  be 
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LAK Precursors Are Distinct from  Memory CTL.  Secondary CTL are achieved from 
memory cell populations by culture with either of the SD or LD signals required for 
the generation of primary CTL (26), and the secondary CTL express lytic activity as 
early as 3 d after activation. These activation conditions are identical to those of LAK, 
since our human IL-2 preparations used for LAK activation are known to contain the 
second signal  functional in  generation of primary CTL  (20).  To test  whether  LAK 
precursors could be memory CTL cells,  we performed several experiments in which 
we studied  the serologic phenotype of memory CTL in  parallel  with  that  of LAK 
precursor  cells.  Our  results  in  Table  III  demonstrated  consistent  eiimination  of 
secondary CTL production from memory populations by depletion with anti-T cell 
antibodies plus C', whereas in  the same cultures  LAK generation was dramatically 
augmented.  Therefore  memory CTL  cells  do  express  the  T  cell  markers  OKT-3, 
OKT-8, and Leu-1, and cells required for LAK generation do not; again OKM-1 had 
no effect on the generation of LAK cells. 
LAK Can Be Generated  from  NK-enriched LGL Populations.  Sedimentation of nonad- 
herent fresh PBL on Percoll gradients (14) was performed to further characterize the 
LAK precursors.  In  10 out of 10 experiments we observed that  the LAK precursors 
sedimented with  the  NK cells.  Modification of the  Percoll  gradient  procedure was 
unsuccessful in separating NK and LAK precursors, though all the LAK precursors 
could be localized in the higher density NK fractions expressing only  1/10th of the 
total  NK activity when the  time  of centrifugation was  increased.  Though we have 
reported previously that LAK are generated from thoracic duct lymphocytes devoid 
of NK activity (1),  it  was uncertain whether NK cells  in  PBL could serve as  LAK 
EFFECTORS 
TARGETS  UNSEP  LGL  SMALLT 
K-562  =  --  :  --  a  l 
i ADAY0 
'° 1 
2.5:1  lo:1  ~:1  2.gi~  lo':1  4o':1 
EFFECTOR:  TARGET 
Fltl.  1.  Percol[  gradient  separation  of  LGL  and  small  T  cells.  Nonadherent  fresh  PBL  were 
separated  into  various densities on  Percoll  gradients  (see Materials  and  Methods).  The 42-45% 
fraction  was further purified  for  NK  cells  by  depletion  of the  29°C  SRBC  rosetting cells;  the 
resulting NK-enriched fraction, called LGL, were 5% of the starting cells, The small, more dense T 
cells from the bottom of the gradient were collected  and lested in parallel; these represented 30% of 
the starting population. Unseparated cells, LGL, and small T  cells were all  tested in parallel on day 
0 for NK activily, and for lysis of the NK resistant tumor (panel A). After 7 d of culture with IL-2 
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precursors. Therefore we further purified the NK cells in the 42-45% Percoll fraction 
by SRBC  rosetting at  29°C  (Fig.  1).  According to previously described results  (14) 
these NK-enriched populations have  been  termed  LGL. On  day 0  after separation, 
the  LGL were observed to display enriched  NK  activity while the T  cells from  the 
bottom of the gradient at 50 and 55% Percoll did not contain such activity toward the 
NK-sensitive target cell K562.  None of the fractions of fresh  PBL  were observed to 
significantly  lyse  the  LAK-sensitive  sarcoma  cell  target.  After  the  fractions  were 
cultured  for  7  d  with  IL-2  they  were  again  tested  for  lysis of K562  and  the  NK- 
resistant sarcoma. The  LAK activity was  found  to be enriched in  the LGL fraction 
and reduced in the T  cell fraction. In six experiments performed using the 29°C high 
affinity rosetting technique to separate NK cells from T  cells, we consistently observed 
that the LAK precursors did not rosette with SRBC at 29°C. 
LAK Precursors Are Serologically Distinct from NK Cells.  Even the most highly purified 
LGL populations are reported to be quite heterogeneous (22) with the active NK cells 
representing an average of 50% of the total cells (27, 28).  Because we were unable to 
distinguish NK cells from the cells required to generate LAK on the basis of Percoll 
sedimentation  and  high  affinity SRBC  rosetting,  we  further  explored  the serologic 
phenotype  of LAK  precursors  using  monoclonal  antibodies  that  were  reported  to 
recognize  NK  cell  antigens,  either  singly  or  in  combination.  Fig.  2  shows  that 
treatment  of nonadherent  fresh  PBL with either Leu-7  (also called HNK-1)  (29)  or 
OKM-1 plus complement significantly reduced or totally eliminated the NK activity, 
respectively. The combination of Leu-7 plus OKM-1 also totally abolished detectable 
NK  activity. After  culture  of the  remaining cells  for  6  d  in  IL-2  to  test  for  LAK 
generation it was found that the Leu-7-depleted population expressed an augmented 
level of LAK, while the OKM-1  and OKM-1  plus Leu-7 were no different from the 
control  untreated  cells.  It  is  not  known  why  the  OKM-l-treated  groups  did  not 
generate an augmented  LAK response as would be expected if LAK precursors were 
enriched.  We can only speculate that  perhaps a  minimal number of monocytes are 
required in activation of LAK cells. 
In  other experiments  we  tested  whether  prior treatment  with  OKT-11,  which  is 
reported to bind T  cells as well as NK cells (30, 31) would eliminate LAK precursors 
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Fie.  2.  LAK precursors are insensitive to anti-NK antibodies  and C'. Fresh nonadherent  PBL 
were treated with the antibodies and C' as shown. The cell recoveries as determined by trypan blue 
exclusion counts immediately after treatment were: none (no treatment), 100%; C' only, 95%; Leu- 
7 + C', 95%; OKM-I + C', 75%; and Leu-7 + OKM-1  + C', 70%. Panel A displays the day 0 NK 
activity of these groups, and panel B, the LAK activity generated after 6 d ofculture in IL-2. 892  IL-2  ACTIVATED  KILLER  CELLS  DISTINCT  FROM  NK  AND  T  CELLS 
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Fro.  3.  LAK precursors are  insensitive to OKT-11  +  C'.  Fresh nonadherent PBL were treated 
with the anti-OKT- 11 and C' as described in Materials and Methods. The cells treated with C' only 
had a  70% recovery,  and the OKT-I 1 +  C' treatment resulted in 3.3% recovery.  Panel A displays 
the NK activity of these populations on day 0, and panel B displays the LAK activity generated 
after 6 d of cuhure in IL-2. 
TABLE  IV 
Distribution of LAK Precursors in Lymphozd Tissues* 
1  PBL  50 
Thymus, I  33 
Thymus, II  57 
2  Spleen  18 
Lymph node  80 
Bone marrow  22 
3  Thoracic duct cells, I  16 
Thoracic duct cells, II  18 
Thoracic duct cells, Ill  67 
*  Single-cell  suspensions were prepared from lymphoid tissues of either normal 
or cancer patients as described in Materials and Methods. The cells  were 
then cultured in IL-2 and assayed for lysis of a sarcoma. 
(Fig.  3).  Our  results  confirm  this,  since 97%  of the  nonadherent  PBL  were  lysed  by 
OKT-11  and  C'  (in  other  experiments  at  least  90%)  and  the  NK  activity  was 
significantly depleted  or abolished.  After culture  for 6  d  in  IL-2,  however,  the LAK 
activity  of the OKT-1  1-depleted  PBL  was  dramatically  augmented,  compared  with 
the control cells. Thus  the cells required  to generate  LAK  appear  to be distinct from 
NK  cells,  since the  LAK  cell  precursors  do  not  express  OKM-1,  Leu-7,  or OKT-1  1, 
whereas NK  cells do express these markers. 
Distribution  of LAK Precursors in Lymphoid  Tissues.  To  determine, whether  the LAK 
precursor cells were unique  to the PBL and thoracic duct lymphocytes  (1) or could be 
found  in  other lymphoid  tissues,  we collected  lymphocytes  from  a  variety of human 
tissue,  cultured  them  for  7  d  in  IL-2  and  tested  them  for  lysis  of an  NK-resistant 
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sarcoma  (Table  IV). We found  that  the  LAK precursors  do exist  in  all the  tissues 
tested,  including  thymus thoracic  duct,  and  in  bone marrow.  In the  mouse  it  was 
reported that LAK could also be generated from tumor-infiltrating lymphocytes (32). 
Therefore, the LAK precursor appears to recirculate and distribute through all of the 
major lymphoid tissues. 
Discussion 
In previous studies (1,  13) we reported that partially purified IL-2 stimulated PBL 
from cancer patients and normals to become lytic for fresh autologous or allogeneic 
tumors,  but  not  to  lymphocytes or  lymphoblasts.  This  system,  which  was  named 
LAK, for lymphokine-activated killer cells, was found to be distinct  from either the 
classic  CTL  or  NK  cell  systems, based  on  a  number  of characteristics  including 
kinetics  of activation,  stimulus requirement,  target  cell  specificity,  precursor  cell 
location,  and  effector cell  phenotype (1).  Therefore  this  study  was  undertaken  to 
further  define  the  cell  type  involved in  the  LAK system.  Our  previous study  had 
shown that monocytes and B lymphocytes found in PBLwere not the direct precursors 
or effectors of LAK cells, leaving mainly T  cells, NK cells, and the ill-defined "null 
cells"  as  candidates.  Our  initial  examination  of the effector cell  phenotype  using 
monoclonal  antibodies  plus  C' showed  that  LAK were sensitive to the  anti-T  cell 
reagents OKT-3, Leu-1, 4F2, but not the monocytereagent OKM-1  (1).  This article 
continues the studies of LAK at both the precursor and effector cell stage, using the 
NK and CTL systems as the positive controls for our reagents. 
We confirmed that LAK effector cells expressed the OKT-3 and OKT-8 phenotype 
of CTL when examined in parallel with allospecific CTL effector cells (Table I). Most 
surprisingly, the LAK precursors appeared totally negative for the same anti-T cell 
reagents that eliminated the development of CTL (Table II). Therefore not only were 
LAK precursors negative for expression of these T  cell markers as determined by our 
C' lysis technique,  but it also suggested that T  cells defined by the antibodies OKT- 
3, Leu-1  (Table II), and OKT-11  (Fig. 3) could not be involved in an accessory role. 
LAK precursors  were  also  found  in  memory CTL  populations.  Since  LAK  are 
generated  under conditions  known  to activate secondary CTL from memory CTL, 
and since the phenotype of memory CTL is not known, we explored the sensitivity of 
memory CTL and  LAK precursors to a  variety of monoclonal antibodies. The pan 
anti-T cell antibodies OKT-3 and  Leu-1  totally eliminated  the 2 °  CTL precursors 
but  resulted  in  an augmented expression of LAK.  Since up  to 95%  of the memory 
CTL were lysed by the Leu-1, it appears that the LAK precursors must be <5% of the 
memory  population.  This  finding  reduces  the  possibility  that  LAK  precursors  in 
cancer patients  represent  memory CTL due  to prior exposure to tumor. The LAK 
precursors  also  appeared  to  be  contained  in  <5%  of the  fresh  nonadherent  PBL 
populations, as demonstrated by the killing of >90% of cells by OKT- 11 plus C' data 
with concomitant augmentation of LAK activity (Fig.  3).  Therefore, if LAK is part 
of the  T  cell  system,  it  is  a  subpopulation  either  resistant  to  C'  lysis  or  one  not 
identified by the commercially available "pan" T  reagent. We have shown (33)  that 
the LAK precursors in the mouse are sensitive to Thy-1 plus C' (the murine pan anti- 
T  cell antibody),  and suggesting that  the human  antibodies  OKT-3, OKT-11, and 
Leu-1 may not recognize an antigen present on all T  cells. 
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extended periods  in  IL-2, and  that  the effector cells  express the CTL phenotype of 
OKT-3 and OKT-8, but  not OKM-1, which is expressed on fresh NK cells  (34).  It 
was not clear from those studies whether the actual NK cell became positive for the 
T cell markers, or whether they resulted merely from expansion of the LAK precursors 
and/or T  cells  contained in the population. Our previous results showed that TDL 
devoid of NK activity generated LAK (1), and therefore some LAK precursors were 
not  NK cells.  Since LAK precursors were found in  the present  study to be distinct 
from T  cells,  it became necessary to further examine their relationship to NK cells  in 
a  controlled  manner.  PercolI  gradient  sedimentation,  followed  by  SRBC  rosette 
depletion ofT cells resulted in enriched NK fractions called LGL. Our results showed 
that  the resultant  NK-rich fraction, and not  the small T  cell  fraction contained an 
enriched  quantity of LAK precursors  (Fig.  1).  However, since these  LGL were not 
pure NK cells  (22), we again applied serologic techniques to examine the relationship 
between LAK and NK cells.  Most LAK precursors were again negative for OKM-1, 
which eliminated NK activity (Fig.  2); LAK activity was augmented by pretreatment 
of PBL with Leu-7 (HNK-1) and also with OKT-I 1 (Fig.  3), which recognizes 95% of 
T cells plus a majority of NK cells. In all cases these antibodies significantly diminished 
or totally abolished  the  NK activity of the  fresh PBL. We have never found LAK 
generation augmented after OKM-1  plus C' treatment,  suggesting that either some 
LAK precursors  are  OKM-I  positive,  or  that  a  small  number  of monocytes are 
required  for LAK activation. Therefore LAK precursors do not express the NK cell 
markers of OKT-11 or Leu-7 and very little if any OKM-1. Since LAK precursors are 
found in all lymphoid tissues  tested (Table IV) and NK cells  are negative in most of 
these  (34-36), we believe this data strongly suggests that the LAK did not originate 
from an active NK cell. 
These results establish  that the LAK precursor is distinct  from the classic CTL or 
NK  cell  (though  this  interpretation  must  be  qualified  to  state  as  determined  by 
antibody  and  C'-mediated  lysis  using  the  pan  T  and  NK  reagents  commercially 
available),  and  as  yet  we  have  no  positive  marker  unique  for  the  human  LAK 
precursor.  We are now employing fluorescent-activated cell  sorting (FACS)  analysis 
and  a  variety of subclass  antibodies  in  an  effort  to  identify the  precursor based on 
techniques  not  dependent  on  C'-mediated  lysis  (E.  Grimm,  L.  Neckers,  and  S. 
Rosenberg,  manuscript  submitted  for  publication).  Our  preliminary  results  from 
FACS analysis have confirmed that LAK precursors appear negative for the markers 
used in this study, plus they appear negative for a number of other T cell and NK cell 
markers;  it  was  found that  LAK precursors are  positive  for T-29/33  (37),  directed 
toward the T200 antigen, which is broadly distributed within leukocytic system but 
not  detectable  on  any  other  cell  types.  A  clear  description  of the  precursor  cell 
phenotype  is  essential  to  understanding  the  nature  of the  LAK  system,  and  its 
relationship to the other cytotoxic phenomena. 
Further  studies  of  both  the  signal(s)  responsible  for  LAK  activation  and  the 
specificity of LAK effectors are currently in progress. Highly purified human IL-2 has 
been found to be stimulatory, and, as yet, no other human lymphokines contained in 
our partially purified  IL-2 appear responsible,  including interferon and IL-1  (E.  A. 
Grimm,  J.  A.  Roth,  R.  Robb,  L.  Neckers,  L.  Lachman,  D.  Wilson,  and  S.  A. 
Rosenberg, manuscript in preparation). The simplicity of LAK activation, its appar- 
ent unique antitumor reactivity, and the broad distribution of LAK precursors suggest GRIMM, RAMSEY, MAZUMDER, WILSON, DJEU, AND ROSENBERG  895 
that  the  LAK  system  may  be  an  expression  of immune  surveillance,  and  most 
intriguingly may provide a simple means for immunotherapy of cancers. 
Summary 
Culture of human peripheral  blood lymphocytes (PBL)  in partially purified  and 
lectin-free interleukin 2 results in the generation of cytotoxic effector cells which have 
the unique property of lysing natural killer (NK)-resistant  fresh human tumor cells. 
We have termed these effector cells "lymphokine-activated killer" cells  (LAK). LAK 
are generated from both normal and cancer patients' PBL and are able to lyse both 
autologous and  allogeneic  tumor  cells  from  all  histologic  tumor  types  tested.  Our 
previous studies  suggested that  the  LAK phenomenon was distinct  from either  the 
cytotoxic thymus-derived lymphocyte (CTL)  or NK systems based  on a  variety of 
criteria.  This study reports that the cell type involved is also distinct, as determined 
by  phenotypic  characteristics.  The  LAK effector  cell  phenotype  was  analyzed  in 
parallel with alloimmune CTL, and  LAK were found to be similarly susceptible to 
the monoclonal anti-T cell antibodies OKT-3 or OKT-8 plus complement. In contrast 
the  LAK  precursor  was  not  susceptible  to  the  OKT-3  or  Leu-1  antibodies  plus 
complement, while the ability to generate alloimmune CTL was totally obliterated 
when tested using the same PBL responder population;  in fact, generation of LAK 
was found to be  augmented five-  to sixfold, clearly suggesting that  LAK precursor 
cells  are  not  T  lymphocytes as  defined  by these  antibodies.  LAK precursors  were 
found to be abundant in NK cell-enriched Percoll gradient fractions, which had been 
depleted of the  29°C  E-rosetting "high affinity" T  cells.  However, LAK precursors 
were found to be distinct from the majority of NK cells  since lysis of fresh PBL with 
the  monoclonal  antibodies  OKM-1,  Leu-7,  or  OKT-11  significantly  depleted  or 
totally  eliminated  NK activity, while  subsequent  activation of the  remaining cells 
generated  high  levels  of LAK and  in  some cases  augmented  levels  of LAK.  LAK 
precursors were found to be distributed in the thymus, bone marrow, spleen, lymph 
node, and thoracic duct in addition to the PBL. Therefore, while the cell(s) responsible 
for activation and expression of LAK activity have some common features with the 
classic T cell-mediated CTL and NK cell systems, the LAK precursor cells are clearly 
distinct  as  determined  by  phenotype  analysis  using  monoclonal  antibodies  and 
complement, and at present must be classified as a "null" cell. 
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